JP2019514943A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514943A5
JP2019514943A5 JP2018557368A JP2018557368A JP2019514943A5 JP 2019514943 A5 JP2019514943 A5 JP 2019514943A5 JP 2018557368 A JP2018557368 A JP 2018557368A JP 2018557368 A JP2018557368 A JP 2018557368A JP 2019514943 A5 JP2019514943 A5 JP 2019514943A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
polypeptide
vaccine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514943A (ja
JP7053491B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030338 external-priority patent/WO2017192418A1/en
Publication of JP2019514943A publication Critical patent/JP2019514943A/ja
Publication of JP2019514943A5 publication Critical patent/JP2019514943A5/ja
Application granted granted Critical
Publication of JP7053491B2 publication Critical patent/JP7053491B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557368A 2016-05-02 2017-05-01 治療用hpvワクチン組み合わせ Expired - Fee Related JP7053491B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662330562P 2016-05-02 2016-05-02
US62/330,562 2016-05-02
US201762447094P 2017-01-17 2017-01-17
US62/447,094 2017-01-17
PCT/US2017/030338 WO2017192418A1 (en) 2016-05-02 2017-05-01 Therapeutic hpv vaccine combinations

Publications (3)

Publication Number Publication Date
JP2019514943A JP2019514943A (ja) 2019-06-06
JP2019514943A5 true JP2019514943A5 (https=) 2020-06-18
JP7053491B2 JP7053491B2 (ja) 2022-04-12

Family

ID=59215960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557368A Expired - Fee Related JP7053491B2 (ja) 2016-05-02 2017-05-01 治療用hpvワクチン組み合わせ

Country Status (12)

Country Link
US (1) US10517944B2 (https=)
EP (1) EP3452087A1 (https=)
JP (1) JP7053491B2 (https=)
CN (1) CN109922829A (https=)
AU (1) AU2017259259B2 (https=)
BR (1) BR112018072372A2 (https=)
CA (1) CA3021341A1 (https=)
IL (1) IL262731A (https=)
MX (1) MX2018013340A (https=)
SG (1) SG11201808809PA (https=)
WO (1) WO2017192418A1 (https=)
ZA (1) ZA201808121B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040440T2 (hu) * 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Hpvポリペプチドおよびil-2をコードするポックスウイルスと抗pd-l1抗体の組合せ
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CN114681603A (zh) * 2020-11-26 2022-07-01 怡道生物科技(苏州)有限公司 基于黑猩猩腺病毒载体的治疗性hpv疫苗、其制备方法及应用
WO2024218165A1 (en) * 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
EP1809750B1 (en) 2004-11-08 2012-03-21 ChromaGenics B.V. Selection of host cells expressing protein at high levels
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
JP5474767B2 (ja) 2007-05-15 2014-04-16 トランジェーヌ、ソシエテ、アノニム 多重遺伝子発現のためのベクター
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9828414B2 (en) 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
HUE040440T2 (hu) * 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
KR20180042295A (ko) * 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신

Similar Documents

Publication Publication Date Title
JP2019514943A5 (https=)
RU2462513C2 (ru) Векторы для множественной генной экспрессии
CA2887623C (en) Pr13.5 promoter for robust t-cell and antibody responses
JP6606571B2 (ja) 治療用hpv16ワクチン
CN103772508B (zh) 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
JP2022160401A5 (https=)
CN101426810A (zh) 基于hpv-18的乳头瘤病毒疫苗
ES2163795T5 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
US10517944B2 (en) Therapeutic HPV vaccine combinations
JP2018519847A5 (https=)
CA2995740A1 (en) Therapeutic hpv18 vaccines
TW200840869A (en) Papillomavirus vaccine
RU2008145712A (ru) Вакцина против папилломовирусной инфекции на основе вируса папиломы человека впч-16
JP2010516287A5 (https=)
JP2020078318A5 (https=)
JP2016510989A5 (https=)
JP2011524863A (ja) 麻疹−ヒトパピローマ混合ワクチン
CN101743250A (zh) 信号传导肽
JP2018521651A (ja) ポックスウイルスにおける発現を増強するためのプロモーター
KR20050083839A (ko) 두개 이상의 우두 ati 프로모터를 포함하는 재조합폭스바이러스
ES2370674T3 (es) Polipéptido e2 de papilomavirus utilizado para la vacunación.
JPWO2021019235A5 (https=)
NZ737583B2 (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
NZ737583A (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
AU2015203893A1 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines